12th Dec 2008 09:15
Sinclair Pharma plc
Directors' Share Dealing
12th December 2008, Godalming, UK: Sinclair Pharma plc ("Sinclair": SPH:L), the international specialty pharmaceutical company, announces that it was notified today that certain directors of the Company acquired new ordinary shares of 1 pence each in the Company ("New Ordinary Shares") following their subscription for shares in the placing announced on 8 December 2008. The details of these share purchases are set out in the table below:
|
Director |
Number of New Ordinary Shares subscribed for |
Price per New Ordinary Share |
Total subsequent holding |
|
|
Number of ordinary shares |
% enlarged issued share capital |
|||
|
Jerry Randall |
400,000 |
£0.16 |
1,187,500 |
1.15% |
|
Penny Freer |
75,000 |
£0.16 |
100,000 |
0.10% |
|
Grahame Cook |
100,000 |
£0.16 |
600,000 |
0.58% |
-ends-
For further information please contact:
Sinclair Pharma plc Tel: +44 (0) 1483 410 600
Dr Michael Flynn, CEO
Jerry Randall, CFO
Mariyam Rawat, Communications & Investor Relations [email protected]
Capital MS&L
Mary Clark, Anna Mitchell Tel +44 (0)20 7307 5340
About Sinclair Pharma Plc www.sinclairpharma.com
Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 80 countries.
Sinclair focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health. Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short timeframe.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.
Related Shares:
Sinclair Pharma